We need more research on psoriasis and psoriatic arthritis
Biomedical research on psoriasis and psoriatic arthritis has greatly accelerated over the last decade, and this research is bearing fruit for patients with psoriatic disease and other health conditions.
When the president of Psoriasis Cure Now testified before Congress in support of psoriasis research funding in 2005, annual psoriasis research funding at the National Institutes of Health (NIH) was stagnant at $6.5 million. This year, it is estimated by NIH at $13 million, a full doubling over the 10 years of Psoriasis Cure Now’s existence.
But this doubling is largely catch-up, as psoriasis research had largely missed the explosive growth in the overall NIH budget in the previous decade. (This short-changing was a driving force in the creation of Psoriasis Cure Now.)
Now, as we move forward, it is important that research on psoriasis and psoriatic arthritis not slip back to its old levels, particularly now that we know how research on psoriatic disease can help us learn about other important health conditions.
It is also important that we educate private sector pharmaceutical and biotech companies about need still unmet by current psoriasis treatments, to encourage them to see the promising market that remains for improved treatment down the road. A desire for psoriasis patients to improve their quality of life can translate into industry investments to bring new treatments to market for our community.
The federal government gets a lot of stuff wrong, but NIH seems to be a place where our tax dollars are being put to good use. Maybe your Member of Congress needs to hear from you about the importance you place on continued investment in psoriasis and psoriatic arthritis research.